stockrowIncyte Corporation
INCYIncyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −277.9%
- Free cash flow
- −233.0%
- Total debt
- −10.5%
Quarter to September 2026, against a year earlier
Follow INCY
Alert me
Incyte Corporation (INCY) Return on invested capital
Incyte Corporation's return on invested capital over the twelve months to 30 September 2026 was 21.6%, down 37.0 percentage points from fiscal 2025 (58.6%). Over the past ten years it has ranged from −31.4% (fiscal 2017) to 58.6% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 58.6% | 55.65 |
| FY2024 | 2.90% | (21.91) |
| FY2023 | 24.8% | (6.38) |
| FY2022 | 31.2% | 6.00 |
| FY2021 | 25.2% | 44.75 |
| FY2020 | −19.6% | (66.87) |
| FY2019 | 47.3% | 31.32 |
| FY2018 | 16.0% | 47.36 |
| FY2017 | −31.4% | (65.91) |
| FY2016 | 34.5% | (3.72) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| EXEL Exelixis, Inc. compare | 66.6% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 59.4% |
| INCY Incyte Corporation | 21.6% |
| ASND Ascendis Pharma A/S compare | 15.1% |
| GMAB Genmab A/S Sponsored ADR compare | 6.89% |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.86% |
| BNTX BioNTech SE Sponsored ADR compare | −34.3% |
| ROIV Roivant Sciences Ltd. compare | −89.9% |
| INSM Insmed, Inc. compare | −247.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement